[go: up one dir, main page]

TWI365185B - Amidophenoxyindazoles useful as inhibitors of c-met - Google Patents

Amidophenoxyindazoles useful as inhibitors of c-met

Info

Publication number
TWI365185B
TWI365185B TW098123519A TW98123519A TWI365185B TW I365185 B TWI365185 B TW I365185B TW 098123519 A TW098123519 A TW 098123519A TW 98123519 A TW98123519 A TW 98123519A TW I365185 B TWI365185 B TW I365185B
Authority
TW
Taiwan
Prior art keywords
amidophenoxyindazoles
inhibitors
met
useful
amidophenoxyindazoles useful
Prior art date
Application number
TW098123519A
Other languages
English (en)
Other versions
TW201006817A (en
Inventor
Tiechao Li
Mark Andrew Pobanz
Chuan Shih
Zhipei Wu
Wei Jennifer Yang
Boyu Zhong
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of TW201006817A publication Critical patent/TW201006817A/zh
Application granted granted Critical
Publication of TWI365185B publication Critical patent/TWI365185B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
TW098123519A 2008-07-24 2009-07-10 Amidophenoxyindazoles useful as inhibitors of c-met TWI365185B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8329408P 2008-07-24 2008-07-24
US8508208P 2008-07-31 2008-07-31
US10865908P 2008-10-27 2008-10-27

Publications (2)

Publication Number Publication Date
TW201006817A TW201006817A (en) 2010-02-16
TWI365185B true TWI365185B (en) 2012-06-01

Family

ID=41010247

Family Applications (1)

Application Number Title Priority Date Filing Date
TW098123519A TWI365185B (en) 2008-07-24 2009-07-10 Amidophenoxyindazoles useful as inhibitors of c-met

Country Status (36)

Country Link
US (2) US8030302B2 (zh)
EP (1) EP2310382B1 (zh)
JP (1) JP5414794B2 (zh)
KR (1) KR101334456B1 (zh)
CN (1) CN102105462B (zh)
AR (1) AR074632A1 (zh)
AT (1) ATE546444T1 (zh)
AU (1) AU2009274256B2 (zh)
BR (1) BRPI0916286B8 (zh)
CA (1) CA2731773C (zh)
CL (1) CL2011000134A1 (zh)
CO (1) CO6351737A2 (zh)
CR (1) CR20110046A (zh)
CY (1) CY1112595T1 (zh)
DK (1) DK2310382T3 (zh)
DO (1) DOP2011000009A (zh)
EA (1) EA018385B1 (zh)
EC (1) ECSP11010778A (zh)
ES (1) ES2379587T3 (zh)
HK (1) HK1155172A1 (zh)
HR (1) HRP20120202T1 (zh)
IL (1) IL210490A (zh)
JO (1) JO2788B1 (zh)
MA (1) MA32594B1 (zh)
MX (1) MX2011000925A (zh)
MY (1) MY163852A (zh)
NZ (1) NZ590013A (zh)
PE (1) PE20110150A1 (zh)
PL (1) PL2310382T3 (zh)
PT (1) PT2310382E (zh)
RS (1) RS52261B (zh)
SI (1) SI2310382T1 (zh)
SV (1) SV2011003816A (zh)
TW (1) TWI365185B (zh)
WO (1) WO2010011538A1 (zh)
ZA (1) ZA201100219B (zh)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011004018A (es) 2008-10-14 2011-06-24 Ning Xi Compuestos y metodos de uso.
JP5583751B2 (ja) 2009-03-21 2014-09-03 クイ ニング アミノエステル誘導体、その塩、及び使用方法
US9133162B2 (en) 2011-02-28 2015-09-15 Sunshine Lake Pharma Co., Ltd. Substituted quinoline compounds and methods of use
WO2012121939A2 (en) * 2011-03-04 2012-09-13 Locus Pharmaceuticals, Inc. Aminopyrazine compounds
KR20130118612A (ko) * 2012-04-20 2013-10-30 (주)네오믹스 신규한 아미노피리딘 유도체 및 이의 용도
JP6129956B2 (ja) * 2012-05-09 2017-05-17 イーライ リリー アンド カンパニー 抗c−Met抗体
EP2961744B1 (en) * 2013-02-27 2017-06-28 Array Biopharma, Inc. Intermediates for use in the preparation of indazole derivatives and processes for the preparation thereof
CN104140393B (zh) * 2013-12-10 2016-09-21 郑州泰基鸿诺医药股份有限公司 一种芳环/芳杂环叔丁醇酯类化合物的制备方法
US20150299219A1 (en) 2014-04-22 2015-10-22 Calitor Sciences, Llc Bicyclic pyrazolone compounds and methods of use
TW201716085A (zh) * 2015-08-12 2017-05-16 應克隆公司 癌症之組合療法
EP3442573A1 (en) * 2016-04-15 2019-02-20 Eli Lilly and Company Combination of ramucirumab and merestinib for use in treatment of colorectal cancer
AU2017273147B2 (en) 2016-06-02 2024-06-13 Immunocore Limited Dosing regimen for GP100-specific TCR - anti-CD3 SCFV fusion protein
US20190269666A1 (en) * 2016-07-29 2019-09-05 Eli Lilly And Company Combination therapy with merestinib and anti-pd-l1 or anti-pd-1 inhibitors for use in the treatment of cancer
CN108069938A (zh) * 2016-11-15 2018-05-25 中国药科大学 2,4-二取代吡啶类化合物及其制备方法和应用
US20200054616A1 (en) 2016-11-16 2020-02-20 Eli Lilly And Company Treatment of cancer with exon 14 skipping mutation(s) or exon 14 skipping phenotype
CN109963562A (zh) 2016-11-16 2019-07-02 伊莱利利公司 用于具有外显子14跳读突变或外显子14跳读表型的癌症的组合疗法
CN107382968A (zh) * 2017-07-06 2017-11-24 北京万全德众医药生物技术有限公司 一种吲哚类c‑Met抑制剂的制备方法
CN107311983A (zh) * 2017-07-06 2017-11-03 北京万全德众医药生物技术有限公司 吲哚类小分子c‑met抑制剂
US10180422B1 (en) 2017-08-22 2019-01-15 Scripps Health Methods of treating a neuroendocrine tumor
EP3480201A1 (en) 2017-11-06 2019-05-08 Oncostellae, S.L. New analogs as androgen receptor and glucocorticoid receptor modulators
JP7377798B2 (ja) 2017-11-24 2023-11-10 南京明徳新薬研発有限公司 c-MET/AXL阻害剤としてのウラシル系化合物
US20210177828A1 (en) * 2018-01-17 2021-06-17 Nanjing Transthera Biosciences Co., Ltd. Tam family kinase /and csf1r kinase inhibitor and use thereof
KR102221689B1 (ko) 2018-03-08 2021-03-02 웰마커바이오 주식회사 티에노피리딘 유도체 및 이를 포함하는 약학적 조성물
WO2020038460A1 (zh) * 2018-08-24 2020-02-27 南京药捷安康生物科技有限公司 一种新型的喹啉衍生物抑制剂
KR20210054548A (ko) 2018-09-03 2021-05-13 타이리간드 바이오사이언스 (상하이) 리미티드 항암 약물로서의 trk 억제제
JP2022554042A (ja) 2019-09-06 2022-12-28 ウェルマーカー・バイオ・カンパニー・リミテッド バイオマーカー型治療用組成物
EP4332106A4 (en) * 2021-06-22 2024-10-30 LG Chem, Ltd. NOVEL COMPOUND AS PROTEIN KINASE INHIBITOR
WO2023110936A1 (en) 2021-12-14 2023-06-22 Netherlands Translational Research Center Holding B.V Reversible macrocyclic kinase inhibitors

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO155316C (no) * 1982-04-23 1987-03-11 Sintef Fremgangsmaate for fremstilling av magnetiske polymerpartikler.
US5484681A (en) * 1994-10-31 1996-01-16 Xerox Corporation Conductive composite particles and processes for the preparation thereof
IL114149A0 (en) * 1995-06-14 1995-10-31 Yeda Res & Dev Modified avidin and streptavidin molecules and use thereof
US5747577A (en) * 1995-12-27 1998-05-05 Xerox Corporation Conductive particles containing carbon black and processes for the preparation thereof
DE10046029A1 (de) 2000-09-18 2002-03-28 Bayer Ag Indazole
EP1400808B1 (en) * 2001-05-18 2006-06-28 Srl, Inc. Immunoassay method
US6956084B2 (en) * 2001-10-04 2005-10-18 Bridgestone Corporation Nano-particle preparation and applications
JP2004067703A (ja) * 2002-04-24 2004-03-04 Japan Science & Technology Corp 架橋ポリマー、微粒子および製造方法
US7192780B2 (en) * 2002-10-23 2007-03-20 Evident Technologies Fluorescent lifetime biological detection and imaging using water-stable semiconductor nanocrystals
CA2503646C (en) 2002-10-28 2011-09-27 Bayer Healthcare Ag Heteroaryloxy-substituted phenylaminopyrimidines as rho-kinase inhibitors
CN102746529B (zh) * 2003-07-17 2015-11-18 生命科技公司 包覆的磁性颗粒的制备方法
US7163998B2 (en) * 2003-09-09 2007-01-16 Eastman Kodak Company Stabilized polymer beads and method of preparation
US7173031B2 (en) * 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7439246B2 (en) 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
BRPI0620292B1 (pt) 2005-12-21 2021-08-24 Janssen Pharmaceutica N. V. Compostos de triazolopiridazinas como moduladores da cinase, composição, uso, combinação e processo de preparo do referido composto
EP2001880A2 (en) * 2006-03-07 2008-12-17 Array Biopharma, Inc. Heterobicyclic pyrazole compounds and methods of use
US9738745B2 (en) * 2006-06-29 2017-08-22 Life Technologies As Particles containing multi-block polymers
PE20080403A1 (es) 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
WO2008051808A2 (en) 2006-10-23 2008-05-02 Sgx Pharmaceuticals, Inc. Bicyclic triazoles as protein kinase modulators
WO2009003084A1 (en) 2007-06-27 2008-12-31 Arkema Inc. Process for the manufacture of hydrofluoroolefins

Also Published As

Publication number Publication date
CN102105462A (zh) 2011-06-22
JP2011529054A (ja) 2011-12-01
CN102105462B (zh) 2014-07-23
RS52261B (en) 2012-10-31
CY1112595T1 (el) 2016-02-10
CO6351737A2 (es) 2011-12-20
ES2379587T3 (es) 2012-04-27
SV2011003816A (es) 2011-03-17
IL210490A0 (en) 2011-03-31
KR20110022691A (ko) 2011-03-07
WO2010011538A1 (en) 2010-01-28
HK1155172A1 (en) 2012-05-11
CL2011000134A1 (es) 2011-07-08
US8030302B2 (en) 2011-10-04
MA32594B1 (fr) 2011-09-01
DOP2011000009A (es) 2011-03-31
PT2310382E (pt) 2012-04-11
KR101334456B1 (ko) 2013-11-29
EP2310382A1 (en) 2011-04-20
EP2310382B1 (en) 2012-02-22
CR20110046A (es) 2011-04-27
US20100022529A1 (en) 2010-01-28
SI2310382T1 (sl) 2012-04-30
MY163852A (en) 2017-10-31
TW201006817A (en) 2010-02-16
BRPI0916286B1 (pt) 2019-10-08
AU2009274256A1 (en) 2010-01-28
EA018385B1 (ru) 2013-07-30
AU2009274256B2 (en) 2013-07-11
MX2011000925A (es) 2011-03-21
PE20110150A1 (es) 2011-03-07
AR074632A1 (es) 2011-02-02
USRE43878E1 (en) 2012-12-25
ECSP11010778A (es) 2011-02-28
ZA201100219B (en) 2012-06-27
IL210490A (en) 2013-06-27
BRPI0916286B8 (pt) 2021-05-25
JO2788B1 (en) 2014-03-15
NZ590013A (en) 2012-06-29
CA2731773A1 (en) 2010-01-28
CA2731773C (en) 2013-03-12
DK2310382T3 (da) 2012-03-26
HRP20120202T1 (hr) 2012-03-31
ATE546444T1 (de) 2012-03-15
EA201170252A1 (ru) 2011-06-30
JP5414794B2 (ja) 2014-02-12
PL2310382T3 (pl) 2012-07-31

Similar Documents

Publication Publication Date Title
TWI365185B (en) Amidophenoxyindazoles useful as inhibitors of c-met
HK1223272A1 (zh) 程序性壞死的小分子抑制劑
HK1156306A1 (zh) 作為 -脯氨酰基- -羥化酶抑制劑的取代的二氫吡唑啉酮類化合物
HRP20130787T1 (en) Imidazopyridazinecarbonitriles useful as kinase inhibitors
HRP20130698T1 (en) Novel phenylpyrazinones as kinase inhibitors
ZA201104749B (en) Benzonaphtyridine compounds used as inhibitors of autotaxin
IL207100A0 (en) 2-amino-quinoline derivatives useful as inhibitors of b-secretase (bace)
GB0621607D0 (en) Inhibitors of c-Met
EP2249650A4 (en) ANILINOPYRIDINE AS A FAK HEMMER
ZA201100898B (en) Novel inhibitors
HK1161680A1 (zh) 作為 抑制劑的吡唑基氨基吡啶
EP2312950A4 (en) COMPOUNDS AS INHIBITORS OF KINASES
ZA201102604B (en) Alkylcyclohexylethers of dihydrotetraazabenzoazulenes
PT2297115E (pt) Derivados de quinazolina
PL2133419T3 (pl) Zastosowania beta-dipeptydów cyjanoficyny
HK1160925A1 (zh) 組織蛋白酶 的用途
IL208916A0 (en) Inhibitors of jnk
GB0821710D0 (en) Derivatives of dihydroindolone
PL386302A1 (pl) Nowa pochodna izotiazolopirydyny
GB0816125D0 (en) Novel inhibitors
GB0621980D0 (en) Inhibitors of c-Met

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees